Prakiraan rega marang bathi: NeurAxis, Inc (NRXS)
The expansion of insurance coverage for neurostimulation in pediatric IBS is stimulating growth, as evidenced by the forward P/E valuation of NeurAxis, Inc. (NRXS). The current level of the 0.00 metric reflects a search for market equilibrium. Revenues are based on the sale of IB-Stim for the therapy of functional abdominal pain. Meanwhile, absolute pricing power in pediatrics is ensured by the uniqueness of the nerve stimulation method.
NeurAxis Inc (NRXS) - rincian metrik lan laporan keuangan
- kuotasi lan prakiraan analis:
- indikator kapitalisasi bursa perusahaan:
- statistik nilai buku emiten:
- data liabilitas lan likuiditas perusahaan:
Rasio Total Utang marang Ekuitas NeurAxis, Inc.|NRXS - Rasio utang jangka dawa marang modal|Utang jangka cendhak marang modal NeurAxis, Inc.|NRXS - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku NeurAxis Inc.|NRXS - Gunggunge utang jangka dawa|Kewajiban jangka cendhak perusahaan NeurAxis|Rasio cepet neuraxis.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
NRXS - Asil keuangan resik|Bathi sing dikarepake NeurAxis, Inc.|NRXS - Pangali rega marang bathi|Pangali Forward P/E NeurAxis, Inc|NRXS - Pangali rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan NeurAxis Inc.|NRXS - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan NeurAxis|NRXS - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan neuraxis.com|NRXS - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep NeurAxis, Inc.
- informasi babagan volume dodolan lan pendapatan:
Analisis dhasar perusahaan:NRXS NeurAxis
The efficiency of the IB-Stim systems expansion and the broadening of insurance coverage in the US directly impact expected profit dynamics, determining the investment attractiveness of NeurAxis, Inc. (NRXS). This ratio is calculated as the current market capitalization divided by projected net income, allowing for an assessment of the cost of each unit of future profit. Analyzing the company's valuation via the forward P/E helps identify imbalances between market quotes and the issuer's fundamental growth potential.
Pesaing utama
Pangali Forward P/E BIIB|NBIX - Rasio prakiraan rega marang bathi|Regencell - Prakiraan rega marang bathi|Pangali Forward P/E Axsome Corp AXSM|ACAD - Rega marang bathi mangsa ngarep|Pangali mangsa ngarep rega marang bathi XENE (xenon-pharma.com)|VKTX: Pangali Forward P/E|Supernus Pharmaceuticals, Inc. (SUPN) - Pangali Forward P/E|Prakiraan rega marang bathi CPRX|Rasio rega marang bathi mangsa ngarep DNLI (Denali Corp)|Pangali Forward P/E HRMY|Kapitalisasi marang proyeksi bathi biohavenpharma.com|Rega marang bathi mangsa ngarep Amylyx Pharmaceuticals, Inc. AMLX|Kapitalisasi marang proyeksi bathi Trevi Therapeutics Inc (TRVI)|PRAX: Prakiraan rega marang bathi|Pangali mangsa ngarep rega marang bathi AVXL (Anavex Life Sciences Corp)|CBLL: Pangali Forward P/E|PRTA - Kapitalisasi marang proyeksi bathi|Rega marang bathi mangsa ngarep Alector Inc.|Rasio rega marang bathi mangsa ngarep ANNX (Annexon Biosciences)|Pangali Forward P/E OMER|Prakiraan rega marang bathi Neurogene Therapeutics NGNE|AC Immune - Prakiraan rega marang bathi|Kapitalisasi marang proyeksi bathi voyagertherapeutics.com (VYGR)|NMRA - Rega marang bathi mangsa ngarep|SCLX (Scilex Holding) - Rasio rega marang bathi mangsa ngarep|Tevogen Bio Holdings, Inc. (TVGN) - Rega marang bathi mangsa ngarep|Alpha Cognition Inc. - Pangali mangsa ngarep rega marang bathi|Prakiraan rega marang bathi CGTX|Rasio rega marang bathi mangsa ngarep IKT (inhibikase.com)|Rega marang bathi mangsa ngarep Cassava Sciences (SAVA)|Kapitalisasi marang proyeksi bathi assertiotx.com|Rega marang bathi mangsa ngarep Coya Therapeutics COYA|VTGN: Rasio rega marang bathi mangsa ngarep|Ovid Rx - Pangali Forward P/E|Rasio prakiraan rega marang bathi acumenpharm.com|CRVO (CervoMed) - Prakiraan rega marang bathi|Alterity Therapeutics Limited (ATHE) - Pangali Forward P/E|Rega marang bathi mangsa ngarep Clene Inc|PEPG: Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Jupiter Neurosciences Inc (JUNS)|RLMD - Rasio prakiraan rega marang bathi|Rega marang bathi mangsa ngarep Annovis Bio ANVS|GRCE: Rasio rega marang bathi mangsa ngarep|Firefly Neuroscience Inc - Pangali Forward P/E|Rasio prakiraan rega marang bathi Klotho Neurosciences Inc|NRSN (neurosense-tx.com) - Prakiraan rega marang bathi|revivapharma.com (RVPH) - Pangali Forward P/E|Rega marang bathi mangsa ngarep MetaVia Inc.|HSDT: Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E PASG|Pangali Forward P/E bionomics.com.au (NEUP)|Minerva Neurosciences - Prakiraan rega marang bathi|ATHA: Rasio rega marang bathi mangsa ngarep|Addex Therapeutics Ltd - Pangali Forward P/E|Kapitalisasi marang proyeksi bathi Alzamend Neuro, Inc. ALZN|cyclerion.com (CYCN) - Rega marang bathi mangsa ngarep|PTIX - Kapitalisasi marang proyeksi bathi|Prakiraan rega marang bathi KTTA|CRGT: Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E ATXI|Kapitalisasi marang proyeksi bathi Brainstorm Cell Therapeutics Inc.|Rega marang bathi mangsa ngarep Cara Therapeutics, Inc CARA|CHRO: Rasio rega marang bathi mangsa ngarep|Eliem - Pangali Forward P/E|Intra-Cellular Therapies (ITCI) - Prakiraan rega marang bathi|LBPH (Longboard Pharmaceuticals, Inc.) - Prakiraan rega marang bathi|MRNS - Kapitalisasi marang proyeksi bathi|Rega marang bathi mangsa ngarep NKGen|Rasio rega marang bathi mangsa ngarep NRBO (NeuroBo Pharma)|Rega marang bathi mangsa ngarep Sage Therapeutics, Inc. (SAGE)|SNPX (synaptogen.com) - Pangali mangsa ngarep rega marang bathi|Trevena - Prakiraan rega marang bathi|VIGL: Rasio rega marang bathi mangsa ngarep|WENA - Rega marang bathi mangsa ngarep|Kapitalisasi marang proyeksi bathi Cerevel Corp CERE
